肾间质纤维化中有氧糖酵解的研究进展  

Advances of aerobic glycolysis in renal interstitial fibrosis

作　　者：张蒙 张璐[1] 王惠明[1] Zhang Meng;Zhang Lu;Wang Huiming(Department of Nephrology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肾内科,武汉430060

出　　处：《中华肾脏病杂志》2023年第2期150-154,共5页Chinese Journal of Nephrology

基　　金：国家自然科学基金青年科学基金(81800614);湖北省技术创新专项(重大项目)(2019ACA137)。

摘　　要：有氧糖酵解是指在氧气充足的情况下,细胞的能量生成仍倾向于低效产能的糖酵解途径,减少对有氧呼吸依赖的同时快速产能,为细胞的生存和增殖提供优势。近年来,多项研究表明有氧糖酵解参与了肾间质纤维化(renal interstitial fibrosis,RIF)的发生发展,且涉及成纤维细胞、内皮细胞、肾小管上皮细胞、周细胞、炎性细胞等多种细胞类型。以糖酵解为治疗靶点的药物可能为RIF的防治策略提供新的思路。本文就RIF中不同细胞异常的有氧糖酵解及糖酵解干预药物的研究进展作一综述。Aerobic glycolysis is a metabolic process in which cellular energy production favors the low-efficiency energy-producing glycolytic pathway in the presence of sufficient oxygen,reducing dependence on aerobic respiration,while producing energy rapidly and providing advantages for cell survival and proliferation.In recent years,several studies have shown that aerobic glycolysis is involved in the development of renal interstitial fibrosis(RIF)and involves various cell types such as fibroblasts,endothelial cells,renal tubular epithelial cells,pericytes,and inflammatory cells.Drugs targeting glycolysis may provide new ideas for the prevention and treatment of RIF.This article reviews the research progress of abnormal aerobic glycolysis in different cells and glycolytic intervention drugs in RIF.

关 键 词：纤维化 糖酵解 肾功能不全 慢性 肾间质 代谢重编程 

分 类 号：R692[医药卫生—泌尿科学]